Biosimilar Awareness Initiative

The Initiative was announced in May 2015 as part of the Pharmaceutical Benefits Scheme Access and Sustainability Package. The aim of the Initiative is to support awareness of, and confidence in, the use of biosimilar medicines for healthcare professionals and consumers.

Page last updated: 01 February 2022

Biosimilar Education

As part of the 2017 budget process the Government agreed to continue its investment in educating prescribers, pharmacists and consumers on the benefits of using biosimilar medicines through supporting the GBMA with a grant to undertake activities to further promote the appropriate prescribing, dispensing and use of biosimilar medicines.

A grant was awarded to GBMA Education Limited in April 2018 to undertake activities to complement and extend the Department’s Biosimilar Awareness Initiative. The total value of the grant is $5 million, with activities under the grant to be completed by December 2020.

Details about the purpose, activities and arrangements for the grant are set out in the Biosimilar Education Grant Opportunity Guidelines:

Further information is available at the GBMA Education website.

This webpage provides information published by the Department of Health as part of the Biosimilar Awareness Initiative.  The Department will continue to publish information supporting biosimilar awareness, including:

Biosimilar medicines Information

Biological medicines currently listed on the Pharmaceutical Benefits Schedule (PBS) can be found on the PBS website.

Biosimilar medicines currently listed on the Pharmaceutical Benefits Schedule (PBS) and approved by the Therapeutic Goods Administration (TGA) are available at 'Which biosimilar medicines are available in Australia?'.

Printable resources – Fact sheets

Biosimilar follitropin alfa

Biosimilar teriparatide

Biosimilar bevacizumab

Biosimilar adalimumab

Biosimilar pegfilgrastim

Biosimilar rituximab

Biosimilar filgrastim

Biosimilar trastuzumab

Biosimilar etanercept

Biosimilar infliximab

Biosimilar Uptake Drivers

The Australian Government is implementing two specific drivers to encourage the use of biosimilar medicines, which will complement the Biosimilar Awareness Initiative.

Information about the uptake drivers can be found on the Biosimilars on the PBS web page.

National Medicines Policy

The Australian Government is a key partner in the National Medicines Policy which supports four central objectives of:

  • timely access to the medicines that Australians need, at a cost individuals and the community can afford;
  • medicines meeting appropriate standards of quality, safety and efficacy;
  • quality use of medicines; and
  • maintaining a responsible and viable medicines industry.

Biosimilar medicines represent a means to further the objectives of the National Medicines Policy, by enhancing access to medicines and by maintaining a competitive market. These objectives also align with the World Health Organization’s definition of the rational use of medicines.

In this section

    Provide feedbackIf you would like a response please complete our enquiries form.

    Comments will be used to improve web content and will not be responded to.

    Real person check

    This form uses a CAPTCHA to ensure that it is submitted by a person, instead of a machine or automated software.

    Privacy statement